Dental
Rochester General Hospital
Rochester General Hospital was paid $226.97M by Medicaid between Jan 2018 and Dec 2024, across 702 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 9.8% of everything it billed.
33Billing provider infoROCHESTER GENERAL HOSPITAL
ROCHESTER, NY 14621
ROCHESTER, NY 14621
33aNPI1255360517assigned 06/30/2006
33bProvider typeGeneral Practice Dentistry
28Total paid$226.97M
24GClaims3,230,816
24DCodes billed702
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Practice Dentistry providers in New York
Rank by total paid#1 of 2,184
Median peer was paid$54K
This provider vs. median4,235×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TINCH, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 77,598 | $3.79M | |
| 2019 | 212,646 | $15.07M | |
| 2020 | 423,633 | $34.42M | |
| 2021 | 675,135 | $43.63M | |
| 2022 | 647,471 | $48.29M | |
| 2023 | 675,490 | $47.68M | |
| 2024incomplete | 518,843 | $34.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.8% | 271,269 | 246,227 | $22.32M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.8% | 224,202 | 200,475 | $19.99M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 7.1% | 105,344 | 70,684 | $16.17M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.4% | 80,214 | 76,060 | $12.14M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.6% | 44,935 | 39,639 | $10.44M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 53,496 | 50,560 | $7.58M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.2% | 50,793 | 48,064 | $7.21M |
| H2019 | Therapeutic behavioral services, billed per 15 minutesTherapeutic behavioral services, per 15 minutes | 3.0% | 9,468 | 9,456 | $6.76M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 2.7% | 56,672 | 43,995 | $6.16M |
| J9271 | Injection, pembrolizumab, 1 mg | 1.8% | 365 | 271 | $4.08M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 51,976 | 50,037 | $4.01M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 1.7% | 21,092 | 17,503 | $3.80M |
690 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 42,128 | $3.38M |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.4% | 11,781 | $3.10M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 18,944 | $2.88M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 10,279 | $2.78M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 9,369 | $2.59M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 41,686 | $2.47M |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | 1.0% | 952 | $2.38M |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 9,676 | $2.18M |
| 80053 | Comprehensive metabolic panel | <1% | 107,613 | $2.04M |
| 59025 | Fetal non-stress test | <1% | 11,136 | $1.90M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 20,374 | $1.63M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 20,654 | $1.58M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 5,019 | $1.52M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 18,951 | $1.48M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,895 | $1.45M |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 4,756 | $1.34M |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 11,841 | $1.32M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 23,604 | $1.29M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 34,056 | $1.15M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,649 | $1.13M |
| 87631 | <1% | 15,511 | $1.08M | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,625 | $1.07M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,419 | $1.04M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 12,461 | $1.02M |
| H2018 | Psychosocial rehabilitation services, per diem | <1% | 2,129 | $980K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 51,821 | $976K |
| 76770 | <1% | 3,884 | $975K | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 8,320 | $964K |
| 96415 | <1% | 2,034 | $925K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 8,708 | $909K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 13,434 | $869K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 30,505 | $859K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 5,674 | $857K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 9,719 | $848K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 34,178 | $848K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,545 | $823K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,911 | $797K |
| 12001 | <1% | 1,891 | $790K | |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 12,332 | $787K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,027 | $783K |
| 36415 | Collection of venous blood by venipuncture | <1% | 106,178 | $749K |
| G0378 | Hospital observation service, per hour | <1% | 3,581 | $736K |
| 94760 | <1% | 15,701 | $728K | |
| 92551 | <1% | 13,118 | $714K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,097 | $713K |
| 97161 | <1% | 7,668 | $679K | |
| 93458 | <1% | 469 | $674K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 2,713 | $667K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,799 | $648K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 907 | $631K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,602 | $631K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 975 | $626K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,567 | $611K |
| 76801 | <1% | 9,243 | $609K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 18,356 | $604K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 35,282 | $584K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,434 | $583K |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 3,879 | $582K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 547 | $554K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 4,494 | $529K |
| S9335 | Home therapy, hemodialysis; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing services coded separately), per diem | <1% | 2,814 | $514K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,410 | $509K |
| 12011 | <1% | 1,207 | $499K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 405 | $487K |
| 10060 | <1% | 1,571 | $486K | |
| 12002 | <1% | 1,140 | $477K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,438 | $471K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 15,348 | $471K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 18,771 | $457K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 4,805 | $448K |
| 47562 | <1% | 194 | $447K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 18,425 | $446K |
| D7240 | Removal of impacted tooth - completely bony | <1% | 1,413 | $437K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,288 | $435K |
| 76830 | Ultrasound, transvaginal | <1% | 7,684 | $403K |
| D0120 | Dental checkup, returning patient | <1% | 9,897 | $395K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,181 | $386K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,222 | $385K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 1,550 | $367K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 9,961 | $356K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,092 | $356K |
| 93970 | <1% | 922 | $355K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 9,131 | $349K |
| 80061 | Lipid panel | <1% | 33,705 | $338K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 3,819 | $336K |
| H0001 | Alcohol and/or drug assessment | <1% | 2,112 | $336K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 852 | $329K |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 1,953 | $307K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 32,730 | $306K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 4,346 | $298K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 9,510 | $293K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 3,470 | $277K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 68,232 | $271K |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 2,006 | $270K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 20,188 | $268K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 12,455 | $267K |
| 88142 | <1% | 10,389 | $263K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 30,394 | $258K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 850 | $258K |
| 86850 | <1% | 9,113 | $256K | |
| 70496 | <1% | 959 | $254K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 816 | $247K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,987 | $243K |
| 93017 | <1% | 1,589 | $240K | |
| 93225 | <1% | 1,726 | $227K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,516 | $226K |
| D1120 | Dental cleaning, child | <1% | 4,507 | $223K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 1,778 | $217K |
| 20610 | <1% | 935 | $213K | |
| 83880 | <1% | 6,500 | $212K | |
| 93971 | <1% | 2,302 | $212K | |
| 71250 | <1% | 1,750 | $204K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13,164 | $203K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,205 | $203K |
| 70491 | <1% | 704 | $200K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,734 | $194K |
| 70486 | <1% | 1,257 | $194K | |
| 93351 | <1% | 684 | $193K | |
| 87660 | <1% | 17,037 | $192K | |
| 90715 | <1% | 7,054 | $189K | |
| D1110 | Prophylaxis - adult | <1% | 3,533 | $187K |
| 86481 | <1% | 3,048 | $185K | |
| 93296 | <1% | 3,105 | $185K | |
| 87480 | <1% | 16,561 | $184K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,486 | $183K |
| 87634 | <1% | 6,279 | $180K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 157 | $180K |
| 87510 | <1% | 16,186 | $177K | |
| 86901 | <1% | 9,573 | $173K | |
| 99385 | <1% | 1,554 | $165K | |
| 99223 | Prolong inpt eval add15 m | <1% | 1,241 | $165K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,797 | $163K |
| 95886 | <1% | 1,752 | $161K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,405 | $160K |
| 73564 | <1% | 4,877 | $156K | |
| 86900 | <1% | 9,564 | $150K | |
| C8930 | Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision | <1% | 499 | $148K |
| 99173 | <1% | 8,307 | $148K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 2,096 | $147K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 5,444 | $144K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 320 | $143K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 98 | $143K |
| 90686 | <1% | 9,626 | $142K | |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 857 | $142K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 10,923 | $140K |
| 77066 | Tomosynthesis, mammo | <1% | 1,903 | $135K |
| 74183 | <1% | 347 | $132K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 21,654 | $127K |
| 76536 | <1% | 2,821 | $127K | |
| 76813 | <1% | 3,218 | $125K | |
| 96367 | <1% | 1,158 | $124K | |
| 86780 | <1% | 12,152 | $122K | |
| 92134 | <1% | 1,657 | $122K | |
| 93226 | <1% | 1,424 | $122K | |
| 88307 | <1% | 1,206 | $116K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 2,286 | $115K |
| 72197 | <1% | 327 | $114K | |
| 82728 | <1% | 10,826 | $111K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,616 | $111K |
| 77080 | <1% | 1,456 | $111K | |
| 97162 | <1% | 939 | $110K | |
| 81025 | <1% | 23,409 | $106K | |
| 73630 | <1% | 5,940 | $105K | |
| 29125 | <1% | 491 | $104K | |
| 90677 | <1% | 1,902 | $102K | |
| H0049 | Alcohol and/or drug screening | <1% | 2,280 | $100K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,599 | $98K |
| 84702 | <1% | 12,538 | $98K | |
| 82607 | <1% | 8,467 | $98K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 1,094 | $97K |
| 36591 | <1% | 1,746 | $96K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 2,238 | $94K |
| 80076 | <1% | 8,425 | $94K | |
| 0071A | <1% | 2,285 | $93K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 1,444 | $93K |
| 88342 | <1% | 1,755 | $93K | |
| 97165 | <1% | 1,178 | $93K | |
| 77336 | <1% | 264 | $92K | |
| 76641 | <1% | 1,743 | $91K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,023 | $91K |
| 72100 | <1% | 3,592 | $91K | |
| 84439 | <1% | 11,556 | $90K | |
| 85027 | <1% | 23,719 | $90K | |
| 90651 | <1% | 2,292 | $88K | |
| D1206 | Topical application of fluoride varnish | <1% | 2,931 | $84K |
| 83970 | <1% | 2,104 | $83K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,944 | $83K |
| 0072A | <1% | 1,984 | $81K | |
| 73221 | <1% | 248 | $81K | |
| 93246 | <1% | 558 | $81K | |
| 86480 | <1% | 1,368 | $80K | |
| 73030 | <1% | 4,176 | $80K | |
| 84484 | <1% | 15,910 | $79K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,671 | $78K |
| 73610 | <1% | 4,913 | $77K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,510 | $77K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 1,260 | $76K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 5,054 | $74K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 979 | $73K |
| 83655 | <1% | 5,403 | $73K | |
| 92133 | <1% | 1,028 | $72K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 43 | $71K |
| 17110 | <1% | 268 | $70K | |
| 76820 | <1% | 2,726 | $70K | |
| 91320 | <1% | 566 | $69K | |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | <1% | 310 | $69K |
| 97597 | <1% | 204 | $68K | |
| 73130 | <1% | 3,941 | $68K | |
| 93320 | <1% | 313 | $67K | |
| 76870 | <1% | 1,004 | $67K | |
| 73562 | <1% | 3,015 | $66K | |
| D9243 | <1% | 885 | $65K | |
| 88304 | <1% | 1,567 | $65K | |
| D0274 | Bitewings - four radiographic images | <1% | 1,853 | $65K |
| 73502 | <1% | 3,228 | $64K | |
| 86803 | <1% | 7,496 | $64K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 626 | $64K |
| 94010 | <1% | 1,320 | $62K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 2,639 | $59K |
| 72141 | <1% | 187 | $59K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 600 | $59K |
| 94060 | <1% | 630 | $58K | |
| 0001A | <1% | 1,473 | $58K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,877 | $57K |
| 76642 | <1% | 1,927 | $57K | |
| 90750 | <1% | 344 | $57K | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 1,238 | $57K |
| 93975 | <1% | 255 | $56K | |
| 93880 | <1% | 428 | $56K | |
| 87081 | <1% | 13,505 | $54K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,878 | $50K |
| 19083 | <1% | 39 | $50K | |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 24 | $49K |
| 82803 | <1% | 1,691 | $49K | |
| 92250 | <1% | 566 | $48K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 178 | $48K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,568 | $47K |
| 76882 | <1% | 1,104 | $47K | |
| 87340 | <1% | 6,715 | $46K | |
| 99188 | <1% | 860 | $46K | |
| 71271 | <1% | 1,354 | $46K | |
| 83550 | <1% | 8,559 | $45K | |
| 85610 | <1% | 11,410 | $45K | |
| 0124A | <1% | 1,055 | $44K | |
| 86762 | <1% | 3,898 | $44K | |
| 83540 | <1% | 9,481 | $44K | |
| 87186 | <1% | 6,966 | $43K | |
| 84403 | <1% | 1,807 | $43K | |
| 43235 | <1% | 73 | $43K | |
| 0002A | <1% | 1,059 | $42K | |
| 99442 | <1% | 856 | $42K | |
| 96160 | <1% | 925 | $42K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 716 | $42K |
| 84153 | <1% | 2,632 | $41K | |
| C1769 | Guide wire | <1% | 714 | $41K |
| 99383 | <1% | 325 | $40K | |
| 82746 | <1% | 3,420 | $40K | |
| 83690 | <1% | 12,713 | $39K | |
| 92083 | <1% | 461 | $39K | |
| 94729 | <1% | 1,502 | $39K | |
| 99406 | <1% | 1,013 | $38K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 1,984 | $38K |
| 95885 | <1% | 336 | $37K | |
| 87077 | <1% | 5,677 | $37K | |
| 95117 | <1% | 1,369 | $37K | |
| 74018 | <1% | 2,668 | $37K | |
| 73110 | <1% | 2,226 | $37K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,620 | $37K |
| 90882 | <1% | 624 | $37K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,474 | $36K |
| 58558 | <1% | 28 | $36K | |
| 83735 | <1% | 8,517 | $36K | |
| 88341 | <1% | 380 | $36K | |
| 72050 | <1% | 1,355 | $35K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 9,808 | $34K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 902 | $34K |
| 90688 | <1% | 1,075 | $34K | |
| 69210 | <1% | 247 | $33K | |
| 80362 | <1% | 4,463 | $33K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 795 | $32K |
| 72110 | <1% | 1,036 | $32K | |
| 86706 | <1% | 4,019 | $32K | |
| 0054A | <1% | 767 | $32K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,320 | $31K |
| 81001 | <1% | 15,394 | $31K | |
| 82570 | <1% | 7,480 | $31K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 12 | $30K |
| 87070 | <1% | 4,568 | $30K | |
| 90680 | <1% | 2,784 | $30K | |
| 80349 | <1% | 5,362 | $29K | |
| G0008 | Administration of influenza virus vaccine | <1% | 2,510 | $29K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 385 | $29K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 371 | $29K |
| 99386 | <1% | 251 | $28K | |
| 74178 | <1% | 145 | $28K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,005 | $28K |
| 84402 | <1% | 1,224 | $28K | |
| 84146 | <1% | 1,520 | $27K | |
| 90682 | <1% | 788 | $27K | |
| 80348 | <1% | 4,315 | $27K | |
| 20611 | <1% | 62 | $26K | |
| 80069 | <1% | 2,017 | $26K | |
| 0052A | <1% | 608 | $26K | |
| 90697 | <1% | 1,454 | $25K | |
| 73140 | <1% | 1,677 | $25K | |
| D9239 | <1% | 883 | $25K | |
| 87088 | <1% | 3,514 | $25K | |
| 82043 | <1% | 5,440 | $25K | |
| 82670 | <1% | 941 | $24K | |
| 0004A | <1% | 585 | $24K | |
| 86140 | <1% | 7,168 | $24K | |
| 81002 | <1% | 9,643 | $24K | |
| 36430 | <1% | 55 | $23K | |
| 0051A | <1% | 559 | $23K | |
| 90633 | <1% | 2,275 | $22K | |
| 87522 | Neg quan hep c or qual rna | <1% | 513 | $22K |
| 90619 | <1% | 973 | $22K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 1,368 | $22K |
| 82784 | <1% | 2,082 | $22K | |
| 87040 | <1% | 3,647 | $22K | |
| D0330 | Panoramic radiographic image | <1% | 468 | $22K |
| 83001 | <1% | 1,333 | $22K | |
| 99443 | <1% | 377 | $21K | |
| D2393 | Resin-based composite - three surfaces, posterior, primary or permanent | <1% | 193 | $21K |
| 90746 | <1% | 560 | $20K | |
| 93356 | <1% | 320 | $20K | |
| 86765 | <1% | 2,114 | $20K | |
| 90670 | <1% | 3,169 | $20K | |
| 95913 | <1% | 168 | $20K | |
| 90656 | <1% | 779 | $20K | |
| 88112 | <1% | 482 | $20K | |
| 96161 | <1% | 464 | $20K | |
| 0081A | <1% | 467 | $20K | |
| 95910 | <1% | 253 | $20K | |
| 93325 | <1% | 253 | $19K | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 276 | $19K |
| 99381 | <1% | 153 | $19K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 222 | $18K |
| 90480 | <1% | 502 | $18K | |
| 82565 | <1% | 4,688 | $18K | |
| 49585 | <1% | 12 | $17K | |
| 73080 | <1% | 906 | $17K | |
| 70487 | <1% | 49 | $17K | |
| 90710 | <1% | 1,475 | $17K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 190 | $17K |
| 82533 | <1% | 1,342 | $17K | |
| 95909 | <1% | 150 | $16K | |
| 90732 | <1% | 360 | $16K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 393 | $16K |
| 86787 | <1% | 2,228 | $16K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 14 | $16K |
| 99384 | <1% | 130 | $16K | |
| 84207 | <1% | 560 | $16K | |
| 29130 | <1% | 78 | $15K | |
| 80306 | <1% | 2,657 | $15K | |
| 90698 | <1% | 2,292 | $15K | |
| 11102 | <1% | 29 | $15K | |
| 83002 | <1% | 890 | $15K | |
| 95115 | <1% | 601 | $15K | |
| 29581 | <1% | 87 | $15K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 95 | $14K |
| 86704 | <1% | 1,755 | $14K | |
| 86038 | <1% | 2,300 | $14K | |
| 94727 | <1% | 309 | $14K | |
| 81508 | <1% | 434 | $14K | |
| 76857 | <1% | 320 | $14K | |
| 74174 | <1% | 53 | $14K | |
| D1351 | Sealant - per tooth | <1% | 289 | $14K |
| 72070 | <1% | 531 | $14K | |
| 84460 | <1% | 4,183 | $14K | |
| 99441 | <1% | 313 | $14K | |
| 90707 | <1% | 632 | $13K | |
| 86618 | <1% | 950 | $13K | |
| 86923 | <1% | 169 | $13K | |
| 86735 | <1% | 1,955 | $13K | |
| 86235 | <1% | 1,050 | $13K | |
| 82947 | <1% | 3,699 | $13K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 825 | $13K |
| 90696 | <1% | 950 | $13K | |
| 80353 | <1% | 1,657 | $13K | |
| 86708 | <1% | 1,796 | $12K | |
| 81003 | <1% | 5,743 | $12K | |
| 90716 | <1% | 588 | $12K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,681 | $12K |
| 84425 | <1% | 778 | $12K | |
| 0082A | <1% | 279 | $12K | |
| 73590 | <1% | 921 | $12K | |
| 87506 | <1% | 96 | $12K | |
| 71101 | <1% | 446 | $11K | |
| 90673 | <1% | 287 | $11K | |
| 86376 | <1% | 904 | $11K | |
| 80347 | <1% | 2,099 | $11K | |
| 84450 | <1% | 2,539 | $11K | |
| 80050 | General health panel | <1% | 443 | $11K |
| 87505 | <1% | 140 | $11K | |
| 96376 | <1% | 2,452 | $11K | |
| 80326 | <1% | 1,924 | $11K | |
| 84480 | <1% | 1,419 | $11K | |
| 84132 | <1% | 3,081 | $11K | |
| 86696 | <1% | 824 | $11K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 363 | $10K |
| 87252 | <1% | 394 | $10K | |
| 96402 | <1% | 253 | $10K | |
| 87272 | <1% | 847 | $10K | |
| 83605 | <1% | 2,164 | $10K | |
| 85652 | <1% | 6,306 | $9K | |
| 83013 | <1% | 196 | $9K | |
| 75561 | <1% | 27 | $9K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 20 | $9K |
| 85014 | <1% | 2,536 | $9K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 290 | $9K |
| 87269 | <1% | 705 | $9K | |
| 85730 | <1% | 2,304 | $9K | |
| 58300 | <1% | 40 | $9K | |
| 90620 | <1% | 298 | $8K | |
| 90734 | <1% | 1,183 | $8K | |
| 83520 | <1% | 878 | $8K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 559 | $8K |
| D4341 | <1% | 92 | $8K | |
| 99152 | <1% | 393 | $8K | |
| 82247 | <1% | 2,391 | $8K | |
| 86141 | <1% | 792 | $8K | |
| D7230 | <1% | 50 | $8K | |
| 84550 | <1% | 2,227 | $8K | |
| 83615 | <1% | 2,117 | $8K | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 26 | $8K |
| 87529 | <1% | 201 | $8K | |
| 70498 | <1% | 68 | $8K | |
| 86705 | <1% | 869 | $8K | |
| 0074A | <1% | 185 | $8K | |
| 99401 | <1% | 152 | $8K | |
| 82550 | <1% | 2,098 | $7K | |
| 99411 | <1% | 210 | $7K | |
| 72040 | <1% | 404 | $7K | |
| 82248 | <1% | 1,684 | $7K | |
| 73090 | <1% | 615 | $7K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 443 | $7K |
| 85379 | <1% | 1,505 | $7K | |
| 87147 | <1% | 2,198 | $7K | |
| 86431 | <1% | 1,621 | $7K | |
| 73560 | <1% | 328 | $7K | |
| 83020 | <1% | 619 | $7K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 123 | $7K |
| 84100 | <1% | 2,021 | $7K | |
| 90662 | <1% | 461 | $6K | |
| 77049 | <1% | 24 | $6K | |
| 0154A | <1% | 155 | $6K | |
| 82950 | <1% | 1,688 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,272 | $6K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,848 | $6K |
| 82310 | <1% | 2,123 | $6K | |
| 11721 | <1% | 73 | $6K | |
| 86160 | <1% | 662 | $6K | |
| 82105 | <1% | 705 | $6K | |
| 75574 | <1% | 50 | $6K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 602 | $6K |
| 86709 | <1% | 751 | $6K | |
| 87209 | <1% | 501 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,518 | $6K |
| 72156 | <1% | 14 | $6K | |
| 97035 | <1% | 305 | $6K | |
| 84520 | <1% | 3,183 | $6K | |
| 82525 | <1% | 467 | $6K | |
| 84156 | <1% | 2,014 | $6K | |
| 72157 | <1% | 12 | $6K | |
| 82040 | <1% | 1,692 | $5K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 180 | $5K |
| 86800 | <1% | 428 | $5K | |
| 99493 | <1% | 67 | $5K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 41 | $5K |
| 83921 | <1% | 301 | $5K | |
| 85018 | <1% | 5,073 | $5K | |
| 86580 | <1% | 842 | $5K | |
| 99382 | <1% | 36 | $5K | |
| 93786 | <1% | 31 | $5K | |
| 90744 | <1% | 1,012 | $5K | |
| 87150 | <1% | 137 | $5K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 158 | $5K |
| 76942 | <1% | 26 | $5K | |
| 76821 | <1% | 132 | $5K | |
| 82274 | <1% | 610 | $5K | |
| 87177 | <1% | 529 | $5K | |
| 84630 | <1% | 534 | $5K | |
| 84295 | <1% | 1,745 | $5K | |
| 86225 | <1% | 711 | $5K | |
| 76825 | <1% | 37 | $4K | |
| 99404 | <1% | 59 | $4K | |
| 99051 | <1% | 405 | $4K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 20 | $4K |
| 84144 | <1% | 191 | $4K | |
| 90713 | <1% | 159 | $4K | |
| 76937 | <1% | 26 | $4K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,387 | $4K |
| 84681 | <1% | 208 | $4K | |
| 82374 | <1% | 1,680 | $4K | |
| 82435 | <1% | 1,724 | $4K | |
| 69209 | <1% | 27 | $4K | |
| 64615 | <1% | 13 | $4K | |
| 80352 | <1% | 657 | $4K | |
| 29075 | <1% | 14 | $4K | |
| 87338 | <1% | 402 | $4K | |
| 87255 | <1% | 147 | $4K | |
| 73718 | <1% | 12 | $4K | |
| 87641 | <1% | 136 | $4K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 64 | $4K |
| 87102 | <1% | 463 | $4K | |
| 84590 | <1% | 331 | $4K | |
| 82150 | <1% | 1,106 | $4K | |
| 87253 | <1% | 195 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,191 | $3K |
| 0012A | <1% | 164 | $3K | |
| 97116 | <1% | 92 | $3K | |
| 84155 | <1% | 1,712 | $3K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 12 | $3K |
| 86003 | <1% | 179 | $3K | |
| 80074 | <1% | 116 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,924 | $3K |
| 84075 | <1% | 1,009 | $3K | |
| 73660 | <1% | 147 | $3K | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 30 | $3K |
| D2332 | <1% | 27 | $3K | |
| 84163 | <1% | 235 | $3K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 95 | $3K |
| 51798 | <1% | 17 | $3K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 54 | $3K |
| 95816 | <1% | 27 | $3K | |
| 94664 | <1% | 71 | $3K | |
| 97164 | <1% | 41 | $3K | |
| 84481 | <1% | 271 | $3K | |
| 84446 | <1% | 218 | $3K | |
| 84597 | <1% | 214 | $3K | |
| 84703 | <1% | 919 | $3K | |
| 83021 | <1% | 168 | $3K | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 130 | $3K |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 517 | $3K |
| 82627 | <1% | 131 | $3K | |
| 93788 | <1% | 31 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,896 | $3K |
| 99177 | <1% | 745 | $2K | |
| 82977 | <1% | 498 | $2K | |
| 0083A | <1% | 59 | $2K | |
| 0011A | <1% | 176 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 560 | $2K |
| 86665 | <1% | 118 | $2K | |
| 86200 | <1% | 369 | $2K | |
| 80164 | <1% | 241 | $2K | |
| 73100 | <1% | 159 | $2K | |
| 84165 | <1% | 398 | $2K | |
| 87536 | <1% | 25 | $2K | |
| 83993 | <1% | 161 | $2K | |
| 92567 | <1% | 186 | $2K | |
| D0272 | Bitewings - two radiographic images | <1% | 105 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,268 | $2K |
| 88141 | <1% | 94 | $2K | |
| 99460 | <1% | 40 | $2K | |
| 91319 | <1% | 81 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,708 | $2K |
| 90837 | Psychotherapy session, about an hour | <1% | 14 | $2K |
| 83721 | <1% | 862 | $2K | |
| 83525 | <1% | 165 | $2K | |
| D0240 | <1% | 95 | $2K | |
| 74220 | <1% | 38 | $2K | |
| 87430 | <1% | 373 | $2K | |
| 72170 | <1% | 42 | $2K | |
| 86039 | <1% | 246 | $2K | |
| 36410 | <1% | 70 | $2K | |
| 80321 | <1% | 85 | $2K | |
| 84145 | <1% | 96 | $2K | |
| 0053A | <1% | 36 | $1K | |
| 76827 | <1% | 37 | $1K | |
| 95911 | <1% | 17 | $1K | |
| D9420 | <1% | 215 | $1K | |
| 80323 | <1% | 168 | $1K | |
| 80354 | <1% | 225 | $1K | |
| 92082 | <1% | 16 | $1K | |
| 80178 | <1% | 236 | $1K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 53 | $1K |
| 98967 | <1% | 16 | $1K | |
| 90381 | <1% | 49 | $1K | |
| D2331 | <1% | 14 | $1K | |
| 98968 | <1% | 21 | $1K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 36 | $1K |
| 0173A | <1% | 29 | $1K | |
| 87449 | <1% | 164 | $1K | |
| 88184 | <1% | 12 | $1K | |
| 92557 | <1% | 43 | $1K | |
| 96127 | <1% | 243 | $1K | |
| 86364 | <1% | 115 | $1K | |
| 96116 | <1% | 26 | $1K | |
| 88312 | <1% | 24 | $1K | |
| 99221 | <1% | 14 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $1K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 37 | $1K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 318 | $1K |
| 92136 | <1% | 14 | $987.31 | |
| 86308 | <1% | 294 | $966.83 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 149 | $964.53 |
| 90700 | <1% | 39 | $923.95 | |
| 97802 | <1% | 28 | $914.41 | |
| 82465 | <1% | 257 | $903.75 | |
| 88173 | <1% | 14 | $865.89 | |
| 84466 | <1% | 75 | $850.70 | |
| 95812 | <1% | 14 | $835.54 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,927 | $826.06 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,340 | $794.49 |
| D1354 | <1% | 15 | $745.05 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,663 | $740.89 |
| 85049 | <1% | 225 | $719.91 | |
| 85045 | <1% | 242 | $714.70 | |
| 96411 | <1% | 24 | $690.48 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 256 | $677.58 |
| 99402 | <1% | 12 | $663.86 | |
| 87653 | <1% | 15 | $661.41 | |
| 73552 | <1% | 27 | $655.73 | |
| 90672 | <1% | 58 | $649.34 | |
| 83516 | <1% | 63 | $595.79 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 32 | $578.26 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 45 | $570.92 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,027 | $542.88 |
| 82785 | <1% | 58 | $536.01 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,423 | $525.03 |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 14 | $512.40 |
| J9045 | Injection, carboplatin, 50 mg | <1% | 17 | $502.61 |
| 86617 | <1% | 25 | $480.52 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,102 | $454.81 |
| 74021 | <1% | 13 | $449.86 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 13 | $442.17 |
| 87205 | <1% | 183 | $432.44 | |
| 72072 | <1% | 24 | $416.63 | |
| 96417 | <1% | 20 | $408.30 | |
| 87324 | <1% | 51 | $390.32 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 14 | $386.75 |
| 80355 | <1% | 38 | $372.26 | |
| 80356 | <1% | 117 | $368.34 | |
| 87075 | <1% | 71 | $367.14 | |
| 86790 | <1% | 37 | $365.05 | |
| 93000 | <1% | 26 | $348.40 | |
| 82951 | <1% | 38 | $333.58 | |
| 72080 | <1% | 12 | $324.36 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $291.18 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 215 | $289.48 |
| 80177 | <1% | 31 | $288.70 | |
| 83014 | <1% | 65 | $261.76 | |
| 72190 | <1% | 12 | $244.71 | |
| 73060 | <1% | 27 | $241.28 | |
| 84152 | <1% | 16 | $230.06 | |
| 90714 | <1% | 12 | $215.83 | |
| 84255 | <1% | 15 | $202.23 | |
| 92015 | Determination of refractive state | <1% | 13 | $189.80 |
| 73070 | <1% | 44 | $186.87 | |
| 72220 | <1% | 12 | $182.92 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 360 | $182.21 |
| 94726 | <1% | 12 | $159.23 | |
| 82378 | <1% | 12 | $153.76 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 37 | $114.28 |
| 80143 | <1% | 394 | $98.40 | |
| 87101 | <1% | 14 | $94.67 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 157 | $91.92 |
| 87207 | <1% | 15 | $88.85 | |
| 80179 | <1% | 355 | $88.41 | |
| 82330 | <1% | 12 | $88.03 | |
| 82952 | <1% | 38 | $84.28 | |
| Q3014 | Telehealth originating site facility fee | <1% | 14 | $83.94 |
| 95012 | <1% | 12 | $80.39 | |
| 84478 | <1% | 14 | $61.07 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 15 | $60.11 |
| 84436 | <1% | 12 | $59.73 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 33 | $53.89 |
| 73600 | <1% | 12 | $52.26 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 583 | $45.17 |
| 91318 | <1% | 12 | $45.08 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 70 | $40.80 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 32 | $20.39 |
| 99495 | <1% | 26 | $17.02 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 194 | $14.95 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 26 | $12.97 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 13 | $12.56 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 13 | $10.66 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 684 | $10.26 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 28 | $3.36 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 15 | $1.16 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 74 | $0.40 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 181 | $0.18 |
| A4657 | Syringe, with or without needle, each | 0% | 515 | $0.00 |
| 99024 | 0% | 16 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 17 | $0.00 |
| 86682 | 0% | 955 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 16 | $0.00 |
| 90648 | 0% | 12 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTINCH, PAULA (SVP- FINANCE)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.